NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s ...

Don't miss the Release Date Trailer for Schrodinger's Cat Burglar, an exploration environmental puzzle game developed by ...

Schrodinger Inc (NASDAQ:SDGR) is among the best medical AI stocks to buy now. Schrodinger Inc (NASDAQ:SDGR)’s management ...

Schrodinger reported strong Q4 2023 results, but weak guidance for 2024, causing a significant drop in the share price. The demand environment continues to impact the software business, with growth ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

Schrodinger's stock has performed well this year due to AI hype and strength in its drug discovery business. While the company appears attractively valued from a long-term perspective, the tight ...

Add Yahoo as a preferred source to see more of our stories on Google. After escaping the Nazis by minutes and then getting smuggled through spy-infested Stockholm, the bomb bay of a British fighter ...

During the last three months, 4 analysts shared their evaluations of Schrodinger (NASDAQ:SDGR), revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ...

Wood's biotech fund owns almost $200 million worth of Schrodinger, about 2% of the company. Here's why she's an investor. Stock-picker Cathie Wood had a fantastic 2020. All five of her funds doubled ...

1 hot IPO plus 1 comparison to Tesla equals 1/3 more stock value. Peering into the future, Citron predicts that Wall Street analysts will "quickly rerate Schrodinger shares much higher," and so it ...